Kazia Therapeutics (KZIA) Competitors $0.88 -0.07 (-7.36%) Closing price 03/28/2025 03:52 PM EasternExtended Trading$0.89 +0.01 (+1.58%) As of 03/28/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KZIA vs. EGRX, INAB, MTEX, CLRB, SNTI, EDSA, BCAB, CMMB, BFRG, and ELEVShould you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Eagle Pharmaceuticals (EGRX), IN8bio (INAB), Mannatech (MTEX), Cellectar Biosciences (CLRB), Senti Biosciences (SNTI), Edesa Biotech (EDSA), BioAtla (BCAB), Chemomab Therapeutics (CMMB), Bullfrog AI (BFRG), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. Kazia Therapeutics vs. Eagle Pharmaceuticals IN8bio Mannatech Cellectar Biosciences Senti Biosciences Edesa Biotech BioAtla Chemomab Therapeutics Bullfrog AI Elevation Oncology Eagle Pharmaceuticals (NASDAQ:EGRX) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, community ranking, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk. Which has stronger valuation & earnings, EGRX or KZIA? Eagle Pharmaceuticals has higher revenue and earnings than Kazia Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEagle Pharmaceuticals$257.55M0.04$35.64MN/AN/AKazia Therapeutics$2.31M1.92-$17.56MN/AN/A Do analysts rate EGRX or KZIA? Kazia Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 1,206.67%. Given Kazia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kazia Therapeutics is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kazia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of EGRX or KZIA? 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.9% of Kazia Therapeutics shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Kazia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is EGRX or KZIA more profitable? Company Net Margins Return on Equity Return on Assets Eagle PharmaceuticalsN/A N/A N/A Kazia Therapeutics N/A N/A N/A Which has more risk and volatility, EGRX or KZIA? Eagle Pharmaceuticals has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500. Does the media prefer EGRX or KZIA? In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than Kazia Therapeutics. MarketBeat recorded 3 mentions for Eagle Pharmaceuticals and 2 mentions for Kazia Therapeutics. Kazia Therapeutics' average media sentiment score of 0.43 beat Eagle Pharmaceuticals' score of 0.25 indicating that Kazia Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Eagle Pharmaceuticals Neutral Kazia Therapeutics Neutral Does the MarketBeat Community believe in EGRX or KZIA? Eagle Pharmaceuticals received 332 more outperform votes than Kazia Therapeutics when rated by MarketBeat users. Likewise, 66.13% of users gave Eagle Pharmaceuticals an outperform vote while only 52.98% of users gave Kazia Therapeutics an outperform vote. CompanyUnderperformOutperformEagle PharmaceuticalsOutperform Votes41266.13% Underperform Votes21133.87% Kazia TherapeuticsOutperform Votes8052.98% Underperform Votes7147.02% SummaryEagle Pharmaceuticals beats Kazia Therapeutics on 7 of the 13 factors compared between the two stocks. Remove Ads Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricKazia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.43M$6.90B$5.63B$7.84BDividend YieldN/A2.75%5.33%4.01%P/E RatioN/A7.2623.5518.73Price / Sales1.92218.61388.1990.75Price / CashN/A65.6738.1734.64Price / Book-0.456.386.894.23Net Income-$17.56M$142.34M$3.20B$247.47M7 Day Performance-9.82%-5.15%-3.06%-2.29%1 Month Performance3.37%-7.55%1.51%-5.81%1 Year Performance-71.59%-11.06%9.35%-0.94% Kazia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIAKazia Therapeutics2.8747 of 5 stars$0.88-7.4%$11.50+1,206.7%-71.6%$4.43M$2.31M0.0012Short Interest ↑Gap UpEGRXEagle PharmaceuticalsN/A$1.45-2.7%N/A-83.2%$18.83M$257.55M0.00100Analyst ForecastNews CoverageGap UpINABIN8bio3.0312 of 5 stars$0.23-2.1%$6.00+2,532.7%-83.4%$18.52MN/A-0.3020Short Interest ↑Gap UpMTEXMannatech0.6999 of 5 stars$9.62-0.8%N/A+7.4%$18.13M$121.55M-11.88250Earnings ReportAnalyst ForecastGap DownCLRBCellectar Biosciences2.0471 of 5 stars$0.39+5.7%$17.67+4,427.6%-91.6%$17.98MN/A-0.2310Analyst ForecastShort Interest ↑SNTISenti Biosciences3.6871 of 5 stars$3.72+1.1%$10.00+168.8%-9.0%$17.97M$2.56M-0.244Short Interest ↓Positive NewsGap UpEDSAEdesa Biotech3.5947 of 5 stars$2.56+2.4%$21.00+720.3%-40.4%$17.90MN/A-1.3720Positive NewsBCABBioAtla2.1158 of 5 stars$0.37+5.4%$6.00+1,521.6%-89.1%$17.89M$11M-0.2260Earnings ReportShort Interest ↑News CoverageGap DownCMMBChemomab Therapeutics3.4706 of 5 stars$1.24-3.1%$9.00+625.8%+45.1%$17.81MN/A-1.2420Short Interest ↓News CoverageBFRGBullfrog AI1.3552 of 5 stars$1.89+7.4%N/A-47.0%$17.79M$60,000.00-2.224Upcoming EarningsShort Interest ↓Positive NewsELEVElevation Oncology2.6229 of 5 stars$0.29-3.4%$3.39+1,067.5%-94.9%$17.17MN/A-0.3540 Remove Ads Related Companies and Tools Related Companies EGRX Alternatives INAB Alternatives MTEX Alternatives CLRB Alternatives SNTI Alternatives EDSA Alternatives BCAB Alternatives CMMB Alternatives BFRG Alternatives ELEV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZIA) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Kazia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KZIA Stock Free KZIA Stock Alerts